

Sander Bins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6358215/publications.pdf>

Version: 2024-02-01

35
papers

902
citations

687363

13
h-index

501196

28
g-index

35
all docs

35
docs citations

35
times ranked

1411
citing authors

#	ARTICLE	IF	CITATIONS
1	Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1229-1254.	3.5	263
2	Individualized Pazopanib Dosing: A Prospective Feasibility Study in Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5738-5746.	7.0	68
3	A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. , 2019, 7, 192.		60
4	Correlation between nivolumab exposure and treatment outcomes in non-“small-cell lung cancer. <i>European Journal of Cancer</i> , 2019, 109, 12-20.	2.8	58
5	Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients. <i>Thyroid</i> , 2020, 30, 966-973.	4.5	57
6	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients. <i>British Journal of Cancer</i> , 2018, 118, 1296-1301.	6.4	49
7	Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer. , 2020, 8, e000586.		39
8	Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2017, 56, 293-303.	3.5	35
9	CYP3A4*22 Genotyping in Clinical Practice: Ready for Implementation?. <i>Frontiers in Genetics</i> , 2021, 12, 711943.	2.3	32
10	UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients. <i>European Journal of Cancer</i> , 2022, 162, 148-157.	2.8	27
11	Polymorphisms in <i>SLCO1B1</i> and <i>UGT1A1</i> are associated with sorafenib-induced toxicity. <i>Pharmacogenomics</i> , 2016, 17, 1483-1490.	1.3	26
12	Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. <i>Clinical Pharmacokinetics</i> , 2019, 58, 651-658.	3.5	20
13	Capecitabine and the Risk of Fingerprint Loss. <i>JAMA Oncology</i> , 2017, 3, 122.	7.1	19
14	Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. <i>Clinical Cancer Research</i> , 2018, 24, 541-546.	7.0	15
15	Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2922-2929.	3.6	15
16	Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS. <i>Bioanalysis</i> , 2016, 8, 123-134.	1.5	12
17	Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study. <i>Clinical Cancer Research</i> , 2017, 23, 1679-1683.	7.0	12
18	Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure. <i>Clinical Pharmacokinetics</i> , 2017, 56, 305-310.	3.5	11

#	ARTICLE	IF	CITATIONS
19	Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer. Drug Resistance Updates, 2022, 62, 100832.	14.4	10
20	Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib. Pharmaceuticals, 2020, 12, 788.	4.5	9
21	Germline Variation in PDCD1 Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy. Cancers, 2021, 13, 1370.	3.7	9
22	The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2020, 85, 547-553.	2.3	8
23	Combining Sorafenib and Immunosuppression in Liver Transplant Recipients with Hepatocellular Carcinoma. Pharmaceuticals, 2021, 14, 46.	3.8	8
24	Individualized Tamoxifen Dose Escalation Letter. Clinical Cancer Research, 2016, 22, 6300-6300.	7.0	7
25	Pembrolizumab Exposure Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance Letter. Clinical Cancer Research, 2019, 25, 3192-3192.	7.0	6
26	Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. Clinical Pharmacology and Therapeutics, 2022, 111, 455-460.	4.7	6
27	Tissue Type Differences in ABCB1 Expression and Paclitaxel Tissue Pharmacokinetics in Patients With Esophageal Cancer. Frontiers in Pharmacology, 2021, 12, 759146.	3.5	5
28	The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients. Pharmaceuticals, 2021, 14, 47.	3.8	4
29	p16 status and choice of chemotherapy in the KEYNOTE-040 study. Lancet, The, 2019, 394, 1322-1323.	13.7	3
30	Landscape of Driver Gene Events, Biomarkers and Druggable Targets Identified by Whole Genome Sequencing of Glioblastomas. Neuro-Oncology Advances, 2022, 4, vdab177.	0.7	3
31	Givosiran Likely Inhibits Cytochrome P450 More Substantially Than Reported. Clinical Pharmacology and Therapeutics, 2022, 112, 24-24.	4.7	3
32	Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma. Pharmacogenomics, 2019, 20, 1283-1290.	1.3	2
33	Correlation between nivolumab exposure and treatment outcome in NSCLC.. Journal of Clinical Oncology, 2018, 36, 9057-9057.	1.6	1
34	Influence of Genetic Variation in COMT on Cisplatin-Induced Nephrotoxicity in Cancer Patients. Genes, 2020, 11, 358.	2.4	0
35	Identifying t cell profiles that associate with clinical response to anti-PD-1 treatment in non-small cell lung carcinoma (NSCLC) patients.. Journal of Clinical Oncology, 2018, 36, e21239-e21239.	1.6	0